Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Restoring effective anti-tumor response in Hodgkin lymphoma with nivolumab

Anas Younes • 9 Jun 2016
EHA 2016
Hodgkin Lymphoma Antibodies Checkpoint inhibitors Nivolumab

Press brief by Anas Younes, MD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.

More from Anas Younes

1:01
Fimepinostat with venetoclax in R/R lymphoma
Anas Younes • 7 Dec 2019
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018

Related Videos

2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:50
Results of the EuroNet-PHL-C1 trial: omission of radiotherapy in children and adolescents with cHL
Christine Mauz-Körholz • 8 Dec 2023
1:17
KEYNOTE-667: pembrolizumab plus COPDAC-28 for high-risk cHL with slow early response to OEPA
Christine Mauz-Körholz • 8 Dec 2023
0:52
Managing late effects of treatment in pediatric patients with Hodgkin lymphoma
Christine Mauz-Körholz • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals